Marinomed Biotech AG Considers Second Cash Capital Increase

Marinomed Biotech AG is evaluating a second cash capital increase of up to 154,053 shares. This follows a previous increase of the same amount. The proposal involves excluding subscription rights of existing shareholders. Negotiations with potential investors are ongoing, yet no definitive agreements or board resolutions have been made.

The Management Board has decided to publish a report on this proposal. This move is designed to meet legal requirements and enable swift action for new capital if necessary. The report will soon be available on Austria's Federal Government electronic platform.

The capital increase seeks to secure short-term financing in line with a restructuring plan. However, the execution depends on investor negotiations, transaction finalization, and approvals from the Management Board, Supervisory Board, and the restructuring administrator.